Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 11/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 12/20 | 0.37 |
| ▸ | AXL | P30530 | 9/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 2/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30412660 | 1.00 | MERTK (0.38) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL25220665 | 0.91 | TYRO3 (0.38) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL30411934 | 0.91 | TYRO3 (0.38) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL30411865 | 0.90 | TYRO3 (0.41) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL25241104 | 0.90 | TYRO3 (0.41) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL25215835 | 0.90 | MERTK (0.37) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL30412173 | 0.90 | MERTK (0.37) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL30411995 | 0.88 | TYRO3 (0.38) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL25205517 | 0.88 | TYRO3 (0.38) | MERTKTYRO3AXLCHEK1FLT3 | |
| SCHEMBL26164228 | 0.88 | LRRK2 (0.37) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215494-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023087027-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ERASCA, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250144094-A1 | THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF | ULK1, ULK2, ULK3 | MERTK 176/4885TYRO3 1554/4885AXL 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.